121 related articles for article (PubMed ID: 2786121)
1. Cytotoxicity and clinical application of activated NK cells.
Lotzová E
Med Oncol Tumor Pharmacother; 1989; 6(1):93-8. PubMed ID: 2786121
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
[TBL] [Abstract][Full Text] [Related]
3. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
Lotzová E; Savary CA; Herberman RB
J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
[TBL] [Abstract][Full Text] [Related]
4. Generation of NK cell activity from human bone marrow.
Lotzová E; Savary CA
J Immunol; 1987 Jul; 139(1):279-84. PubMed ID: 3495600
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 corrects defective NK activity of patients with leukemia.
Lotzová E; Savary CA
Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):169-75. PubMed ID: 3491726
[TBL] [Abstract][Full Text] [Related]
6. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
[TBL] [Abstract][Full Text] [Related]
7. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
8. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
11. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
Tarkkanen J; Saksela E; Lanier LL
J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
13. Immunologic and clinical aspects of natural killer cells in human leukemia.
Lotzová E; Savary CA; Pollock RE; Fuchshuber P
Nat Immun Cell Growth Regul; 1990; 9(3):173-81. PubMed ID: 2370877
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
15. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
16. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer.
Lotzová E; Savary CA; Freedman RS; Edwards CL; Wharton JT
Int J Cancer; 1988 Aug; 42(2):225-31. PubMed ID: 3261280
[TBL] [Abstract][Full Text] [Related]
17. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
19. Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells.
Itoh K; Platsoucas CD; Tilden AB; Pollock RE; Balch CM
Cell Immunol; 1987 Sep; 108(2):283-96. PubMed ID: 3113741
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
